Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Age ≥ 18 years
* Localized or locally advanced soft tissue sarcoma of extremity proven by biopsy histological grade 2 and 3.
* Pathological expert proof-reading in reference centers
* HFRT and surgery planned (regardless the potential inclusion in this trial) as decided in a multidisciplinary tumor board, in reference centre (European Society for Medical Oncology (ESMO) guideline 2021)
* R0 surgery is feasible, in reference centers
* Pre-biopsy MRI available
* Performance status of 0-2 and life expectancy of at least 6 months

Exclusion Criteria:

* Patient who cannot undergo MRI
* Patients with localized or locally advanced soft tissue sarcoma of extremity proven by biopsy with histological grade 1
* Previous radiation in the area
* Woman who is pregnant or breastfeeding
* Soft tissue sarcoma developed in irradiated area.
* Patients with myxoid liposarcoma, embryonal or alveolar rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, angiosarcoma, primitive neuroectodermal tumor, desmoid-type fibromatosis, or dermatofibrosarcoma protuberans
* Patient with metastatic disease, other concomitant cancer or history of cancer treated and controlled within the previous 3 years.